Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18897507 | 1.00 | DDB1 (0.43) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL20564793 | 1.00 | DDB1 (0.43) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL1963747 | 0.91 | HPGD (0.44) | DDB1CRBNUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL1965378 | 0.86 | MAPT (0.49) | DDB1CRBNUSP2SMN1; SMN2MAPT | |
| SCHEMBL7975740 | 0.84 | MEN1 (0.59) | SMN1; SMN2ESR2MAPTMEN1KMT2A | |
| SCHEMBL954970 | 0.84 | NR1H2 (0.43) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL15227433 | 0.83 | USP2 (0.41) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL104498 | 0.83 | USP2 (0.44) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL12908934 | 0.83 | USP2 (0.44) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL21241481 | 0.83 | USP2 (0.44) | DDB1CRBNUSP2SMN1; SMN2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 840 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385849-B | Method for purifying N-Boc-3-fluoro-4-piperidone | 南通瑞合达医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115385849-A | Method for purifying N-Boc-3-fluoro-4-piperidone | 南通瑞合达医药科技有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-114853768-A | Method for synthesizing chiral 3-fluoro-1-azabicyclo [2,2,1] heptane | 南昌大学 | 2022-08-05 | — | — | CN | claimed |
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| US-20030064978-A1 | Novel compounds | ASTRAZENECA AB. (SE) | 2003-04-03 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| US-5837715-A | 3-fluoro-4-aminopiperidine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | DDB1 3788/4885CRBN 3806/4885USP2 4855/4885 |
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, CCNC, CDK6 | DDB1 209/4885CRBN 83/4885USP2 2411/4885 |
| US-20030064978-A1 | Novel compounds | NOS1, NOS3, NOS2 | DDB1 4191/4885CRBN 2656/4885USP2 1260/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | DDB1 1408/4885CRBN 363/4885USP2 2569/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | DDB1 992/4885CRBN 179/4885USP2 1404/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | DDB1 79/4885CRBN 1490/4885USP2 1735/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 823/4885CRBN 25/4885USP2 63/4885 |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | ALPI, POLR1C, POLI | DDB1 2195/4885CRBN 3894/4885USP2 3755/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | DDB1 3723/4885CRBN 4454/4885USP2 736/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | DDB1 270/4885CRBN 277/4885USP2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.